OptiBiotix Health PLC Distributor agreement for LPLDL(R) (1803D)
February 17 2020 - 02:06AM
UK Regulatory
TIDMOPTI
RNS Number : 1803D
OptiBiotix Health PLC
17 February 2020
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Appointment of Advanced NutriSolutions Inc./Select Ingredient as
exclusive distributor for LP(LDL) (R) in the United States and
Canada
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its wholly-owned subsidiary ProBiotix
Health Ltd. ("ProBiotix"), has signed a distributor agreement with
Advanced NutriSolutions Inc./Select Ingredient for the exclusive
sales of ProBiotix's patented probiotic strain LP(LDL) (R) into the
United States and Canada. Market exclusivity is linked to a six
month time to first order and sales volumes
Under the terms of the agreement, Advanced NutriSolutions
Inc./Select Ingredient will supply ProBiotix's cholesterol and
blood pressure-reducing probiotic strain Lactobacillus plantarum
LP(LDL) (R), under an exclusive licence, to customers in the United
States and Canada for inclusion into dietary supplements
formulation.
Advanced NutriSolutions Inc./Select Ingredient was founded in
1994 by Dr. Bruce Howe. It supplies nutritional ingredients,
contract manufacturing services, and finished products to the
nutritional supplement industry. Advanced NutriSolutions
Inc./Select Ingredient serves the United States and Canada from its
facilities located in San Diego, California.
Steve Prescott, CEO of ProBiotix, commented: " We are pleased to
announce this distributor agreement with Advanced NutriSolutions
Inc./Select Ingredient , which will expand LP(LDL) (R)'s reach and
service level in the United States and Canada. Advanced
NutriSolutions Inc./Select Ingredient was chosen as our partner in
this important region because of their technical expertise in
functional ingredients including probiotics, their industry
reputation, and their manufacturing capabilities which allows them
not only to sell LP(LDL) (R) as an ingredient but to also create
custom formulation and products for customers."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking) Tel: 020 7220 0500
Goetz Partner Securities Limited
Ulrich Kinzel Tel: 020 3897 7725
Walbrook PR Ltd
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCTRMRTMTMBMJM
(END) Dow Jones Newswires
February 17, 2020 02:06 ET (07:06 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2023 to Mar 2024